BioVie Inc

BIVI

Company Profile

  • Business description

    BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

  • Contact

    680 W Nye Lane
    Suite 204
    CarsonNV89703
    USA

    T: +1 775 888-3162

    E: [email protected]

    https://www.bioviepharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    14

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,688.0035.50-0.41%
CAC 407,565.5724.09-0.32%
DAX 4023,320.0130.54-0.13%
Dow JONES (US)42,206.8235.160.08%
FTSE 1008,762.4012.25-0.14%
HKSE23,659.74129.260.55%
NASDAQ19,447.4198.86-0.51%
Nikkei 22538,354.0949.14-0.13%
NZX 50 Index12,532.6536.40-0.29%
S&P 5005,967.8413.03-0.22%
S&P/ASX 2008,474.9030.60-0.36%
SSE Composite Index3,381.5821.690.65%

Market Movers